Literature DB >> 2120825

Persistence of the carrier status in haemorrhagic septicaemia (Pasteurella multocida serotype 6:B infection) in buffaloes.

M C de Alwis1, T G Wijewardana, A I Gomis, A A Vipulasiri.   

Abstract

Fifty-seven young buffaloes were experimentally infected or naturally exposed to haemorrhagic septicaemia (HS). Of these animals 32 became immune carriers. They were observed in groups for periods up to 360 days to monitor the appearance of pasteurellae in the nasopharynx and antibody status. In most animals pasteurellae appeared in the nasopharynx for a short period initially and disappeared. The organism reappeared intermittently and the longest observed period of reappearance was 215 days after exposure. All animals showed rising antibody titres with a peak lasting for 150 to 180 days and declining thereafter. Pasteurellae persisted in the tonsils and were isolated from 20 out of 27 carriers after slaughter. The longest period when isolation was made after slaughter was 229 days. The organism lodged in the tonsils was unaffected by antibacterial therapy using drugs to which the organism displayed in vitro sensitivity. It is concluded that in HS, carrier animals exist in an active as well as a latent state, the former appearing for short intermittent periods between long latent periods, when pasteurellae continue to remain in the tonsils which constitute a long-term reservoir.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120825     DOI: 10.1007/bf02241015

Source DB:  PubMed          Journal:  Trop Anim Health Prod        ISSN: 0049-4747            Impact factor:   1.559


  8 in total

1.  Studies on Pasteurella multocida. I. A hemagglutination test for the identification of serological types.

Authors:  G R CARTER
Journal:  Am J Vet Res       Date:  1955-07       Impact factor: 1.156

2.  Carrier rate of Pasteurella multocida in a cattle herd associated with an outbreak of haemorrhagic septicaemia in the Sudan.

Authors:  A A Mustafa; H W Ghalib; M T Shigidi
Journal:  Br Vet J       Date:  1978 Jul-Aug

3.  A study of immunity against pasteurella multocida in buffalo calves and their carrier status.

Authors:  K Mohan; M N Sinha; R P Singh; C M Gupta
Journal:  Vet Rec       Date:  1968-08-10       Impact factor: 2.695

4.  Studies on the occurrence of Pasteurella multocida in the nasopharynx of healthy cattle.

Authors:  E A Wijewanta; K G Karunaratne
Journal:  Cornell Vet       Date:  1968-07

5.  Naturally acquired immunity to haemorrhagic septicaemia among cattle and buffaloes in Sri Lanka.

Authors:  M C de Alwis; M A Sumanadasa
Journal:  Trop Anim Health Prod       Date:  1982-02       Impact factor: 1.559

6.  Haemorrhagic septicemia carrier status of cattle and buffaloes in Sri Lanka.

Authors:  T Hiramune; M C de Alwis
Journal:  Trop Anim Health Prod       Date:  1982-05       Impact factor: 1.559

7.  Immune status of buffalo calves exposed to natural infection with haemorrhagic septicaemia.

Authors:  M C de Alwis
Journal:  Trop Anim Health Prod       Date:  1982-02       Impact factor: 1.559

8.  Mortality among cattle and buffaloes in Sri Lanka due to haemorrhagic septicaemia.

Authors:  M C de Alwis
Journal:  Trop Anim Health Prod       Date:  1981-11       Impact factor: 1.559

  8 in total
  10 in total

1.  Demonstration of Pasteurella multocida type 6:B (B:2) in formalin-fixed paraffin-embedded tissues of buffaloes by the peroxidase anti-peroxidase (PAP) technique.

Authors:  N Horadagoda; K Belák
Journal:  Acta Vet Scand       Date:  1990       Impact factor: 1.695

2.  Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves.

Authors:  Mark P Dagleish; J Christopher Hodgson; Saeed Ataei; Anna Finucane; Jeanie Finlayson; Jill Sales; Roger Parton; John G Coote
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

3.  Septicemic pasteurellosis causing peracute death and necrotizing myositis in a beef heifer calf (Bos taurus) in Alberta, Canada.

Authors:  Douglas Doyle-Baker; Musangu Ngeleka; Eugene Janzen; Robert E Briggs; Jennifer L Davies
Journal:  Can Vet J       Date:  2020-12       Impact factor: 1.008

4.  Protective effect following intranasal exposure of goats to live Pasteurella multocida B:2.

Authors:  M Zamri-Saad; Z A Ernie; M Y Sabri
Journal:  Trop Anim Health Prod       Date:  2006 Oct-Nov       Impact factor: 1.559

5.  Efficacy of an inactivated recombinant vaccine encoding a fimbrial protein of Pasteurella multocida B:2 against hemorrhagic septicemia in goats.

Authors:  Ina-Salwany Mohd Yasin; Sabri Mohd Yusoff; Zamri-Saad Mohd; Effendy Abd Wahid Mohd
Journal:  Trop Anim Health Prod       Date:  2010-08-10       Impact factor: 1.559

6.  Proliferation and transmission patterns of Pasteurella multocida B:2 in goats.

Authors:  M S Shafarin; M Zamri-Saad; B Siti Khairani; A A Saharee
Journal:  Trop Anim Health Prod       Date:  2008-06       Impact factor: 1.559

7.  Evaluation of Pasteurella multocida serotype B:2 resistance to immune serum and complement system.

Authors:  Saeed Ataei Kachooei; Mohammad Mehdi Ranjbar; Saba Ataei Kachooei
Journal:  Vet Res Forum       Date:  2017-09-15       Impact factor: 1.054

8.  In vitro treatment of lipopolysaccharide increases invasion of Pasteurella multocida serotype B:2 into bovine aortic endothelial cells.

Authors:  Seng Kar Yap; Zunita Zakaria; Siti Sarah Othman; Abdul Rahman Omar
Journal:  J Vet Sci       Date:  2018-03-31       Impact factor: 1.672

9.  New sites of localisation of Pasteurella multocida B:2 in buffalo surviving experimental haemorrhagic septicaemia.

Authors:  Salleh Annas; Mohammad Zamri-Saad; Faez Firdaus Abdullah Jesse; Zakaria Zunita
Journal:  BMC Vet Res       Date:  2014-04-11       Impact factor: 2.741

10.  A retrospective study on the epidemiology of anthrax, foot and mouth disease, haemorrhagic septicaemia, peste des petits ruminants and rabies in Bangladesh, 2010-2012.

Authors:  Shankar P Mondal; Mat Yamage
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.